BsAb R4-21/R4-1a-51 scFv for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
BsAb R4-21/R4-1a-51 scFv may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed bsAb R4-21/R4-1a-51 scFv in detail.
, Development of bispecific antibodies with enhanced neutralization activity against tested SARS-CoV-2 Omicron subvariants, Frontiers in Immunology, doi:10.3389/fimmu.2026.1793368
Background The COVID-19 pandemic, driven by the SARS-CoV-2 virus, has posed significant global health challenges, exacerbated by the emergence of the highly mutable Omicron variant. This study explores the potential of bispecific antibodies (bsAbs) in neutralizing this variant more effectively compared to traditional monoclonal antibodies (mAbs) and their combinations. Materials and methods A comprehensive approach was utilized involving a fully human antibody phage-display library, Omni-Mab, to identify and enrich phage clones specific to SARS-CoV-2. Recombinant spike receptor-binding domain (RBD) proteins from the Omicron variant and other strains served as antigens during the biopanning process to ensure a broad screening. Post-enrichment, the binding affinity of the antibodies to the spike proteins of various strains was rigorously evaluated. Antibodies demonstrating strong binding efficacy were strategically combined and engineered into bsAbs. The neutralizing efficacy of these bsAbs was subsequently tested using various strains of the SARS-CoV-2 pseudo-viruses. Results Selected parental mAbs showed kinetic profiles ranging from 5.71 x 10– 10 to 2.53 x 10– 4 M across the tested Omicron subvariants, and the lead bsAbs, particularly R3-1a-1/R4-1a-10 and R4-21/R4-1a-51, demonstrated enhanced binding activity and lower IC50 values than the controls and mAb cocktails. Conclusion The research unveiled two highly promising bsAbs, namely, R3-1a-1/R4-1a-10 scFv and R4-21/R4-1a-51 scFv. These bsAbs showed strong binding and neutralizing activity across the tested Omicron subvariants and retained activity against selected non-Omicron pseudovirus strains evaluated in this study.